The c-myb proto-oncogene: a novel target for human gene therapy

  • Alan M. Gewirtz
Part of the Cancer Treatment and Research book series (CTAR, volume 84)


The hypothesis that viruses could cause cancer was initially viewed with great skepticism but is now firmly accepted. Using recombinant technology, it has been proven beyond any doubt that retroviruses in particular contain within their genomes transforming genes capable of inducing neoplastic transformation [1,2]. These viral oncogenes have (v-onc) been shown to be derived from highly conserved, normal cellular genes that were almost certainly incorporated into the viral genome during its transit through the host cell. The normal cellular counterparts of the v-onc genes are termed proto-oncogenes. Proto-oncogenes in turn have been shown to be intimately involved in the processes of cell proliferation and differentiation. They encode, for example, proteins that function as growth factors or growth factor receptors [3,4], signal transducing proteins [5], and a large number of proteins with transcriptional activity [6,9]. Accordingly, it is not difficult to imagine situations where v-onc (1) amplification [10], (2) mutation [11], (3) translocation leading to structural alteration [12], or (4) change in transcriptional regulation might either lead to, or be associated with, induction of a malignant phenotype in the cell in which these changes occurred [1,13].


Chronic Myelogenous Leukemia Polycythemia Vera Antisense Oligodeoxynucleotides Hs294T Cell SCID Mouse Model 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bishop MJ (1991). Molecular themes in oncogenesis. Cell 64:235–248.PubMedCrossRefGoogle Scholar
  2. 2.
    Bruck KB, Liu ET, Larrick JW (1988). Viruses and oncogenes. In Bruck KB, Liu ET, Larrick JW (eds), Oncogenes: An Introduction to the Concept of Cancer Genes. Springer-Verlag: New York, pp. 38–66.Google Scholar
  3. 3.
    Sherr CJ, Rettenmeier CW, Sacca R, Roussel MF, Look AT, Stanley ER (1985). The c-fms protooncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1. Cell 41:665–676.PubMedCrossRefGoogle Scholar
  4. 4.
    Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Ghen E, Schlessinger J, Francke U, Ullrich A (1987). Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO 6:3341–3351.Google Scholar
  5. 5.
    Bos JL (1989). ras oncogenes in human cancer: Review. Cancer Res 49:4682–4689.PubMedGoogle Scholar
  6. 6.
    Bohmann D, Bos TJ, Admon A, Nishimura T, Vogt PK, Tjian R (1987). Human protooncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1. Science 238:1386–1392.PubMedCrossRefGoogle Scholar
  7. 7.
    Ransone LJ, Verma IM (1990). Nuclear proto-oncogenes fos and jun. Annu Rev Cell Biol 6:539–557.PubMedCrossRefGoogle Scholar
  8. 8.
    Hasegawa T, Hara E, Takehana K, Nakada S, Oda K, Kawata M, Kimura H, and Sekiya S (1991). A transient decrease in N-myc expression and its biological role during differentiation of human embryonal carcinoma cells. Differentiation 47:107–117.PubMedCrossRefGoogle Scholar
  9. 9.
    Biedenkapp H, Borgmeyer U, Sippel AE, Klempnauer KH (1988). Viral myb oncogene encodes a sequence-specific DNA-binding activity. Nature 335:835–837.PubMedCrossRefGoogle Scholar
  10. 10.
    Schwab M (1994). Human neuroblastoma: amplification of the N-myc oncogene and loss of a putative cancer-preventing gene on chromosome 1p. Recent Results Cancer Res 135:7–16.PubMedGoogle Scholar
  11. 11.
    Cerutti P, Hussain P, Pourzand C, Aguilar F (1994). Mutagenesis of the H-ras protooncogene and the p53 tumor suppressor gene. Cancer Res 54 (Suppl 7):1934s-1938s.PubMedGoogle Scholar
  12. 12.
    Shtivelman E, Lifshitz B, Gale RP, Canaani E (1985). Fused transcript of abl and bcr genes in chronic meyleogneous leukemia. Nature 315:550–554.PubMedCrossRefGoogle Scholar
  13. 13.
    Slamon D (1987). Protooncogenes and human cancer. N Engl J Med 317:955–957.PubMedCrossRefGoogle Scholar
  14. 14.
    Waldman T (1992). Targeted homologous recombination in mammalian cells. Crit Rev Oncol/Hematol 12:49–64.CrossRefGoogle Scholar
  15. 15.
    Moser HE, Dervan PB (1987). Sequence specific cleveage of double helical DNA by triple helix formation. Science 234:645–650.CrossRefGoogle Scholar
  16. 16.
    Stein CA, Cheng YC (1993). Antisense oligonucleotide as therapeutic agents — is the bullet really magical? Science 261:1004–1012.PubMedCrossRefGoogle Scholar
  17. 17.
    Snyder DS, Yaping W, Wang JL, Rosi JJ, Swiderski P, Kaplan BK, Forman SJ (1993). Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. Blood 82:600–605.PubMedGoogle Scholar
  18. 18.
    Agrawal S, Tang JY (1992). GEM 91 — an antisense oligodeoxynucleotide phosphorotioate as a specific therapeutic agent for AIDS. Antisense Res Dev 2:261–266.PubMedGoogle Scholar
  19. 19.
    Gewirtz AM, Calabretta B (1988). A c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro. Science 245:1303–1306.CrossRefGoogle Scholar
  20. 20.
    Chiang MY, Chan H, Zounes MA, Freier SM, Lima WF, Bennett CF (1991). Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J Biol Chem 266:18162–18171.PubMedGoogle Scholar
  21. 21.
    Cardoso AA, Li MA, Batard P, Hatzfeld A, Brown EL, Levesque JP, Sookedo H, Panterne B, Sansilvestrini P, Clark SC, Hatzfeld J (1993). Release from quiescence of CD34+ CD38-human umbilical cord blood cells reveals their potentiality to engraft adults. Proc Natl Acad Sci USA 90:8707–8711.PubMedCrossRefGoogle Scholar
  22. 22.
    Ratajczak MZ, Luger SM, DeRiel K, Abrahm J, Calabretta B, Gewirtz AM (1992). Role of the KIT protooncogene in normal and malignant human hematopoiesis. Proc Natl Acad Sci USA 89:1710–1714.PubMedCrossRefGoogle Scholar
  23. 23.
    Skorski T, Szczylik C, Ratajczak MZ, Malaguarnera L, Gewirtz AM, Calabretta B (1992). Growth factor-dependent inhibition of normal hematopoiesis by N-ras antisense oligodeoxynucleotides. J Exp Med 175:743–750.PubMedCrossRefGoogle Scholar
  24. 24.
    Small D, Levenstein M, Kim E, Carow C, Amin S, Rockwell P, Witte L, Burrow C, Ratajczak MZ, Gewirtz AM, Civin CI (1994). STK-1, the human homologue of FlK-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci 91:459–463.PubMedCrossRefGoogle Scholar
  25. 25.
    Luescher B, Eisenman RN (1990). New light on Myc and Myb. Part II. Myb. Genes Dev 4:2235–2242.CrossRefGoogle Scholar
  26. 26.
    Lyon J, Robinson C, Watson R (1994). The role of the Myb proteins in normal and neoplastic cell proliferation. Crit Rev Oncogen 5:373–388.Google Scholar
  27. 27.
    Sakura H, Kanei-Ishii C, Nagase T, Nakagoshi H, Gonda TJ, Ishii S (1989). Delineation of three functional domains of the transcription activator encoded by the c-myb protooncogene. Proc Natl Acad Sci USA 86:5758–5762.PubMedCrossRefGoogle Scholar
  28. 28.
    Cogswell JP, Cogswell PC, Kuehl M, Cuddihy AM, Bender TM, Engelke U, Marcu KB, Ting JP-Y (1993). Mechanism of c-myc regulation by c-myb in different cell lineages. Mol Cell Biol 13:2858–2869.PubMedGoogle Scholar
  29. 29.
    Foos G, Natour S, Lempnauer KH (1993). TATA-box dependent transactivation of the human HSP70 promoter by Myb proteins. Oncogene 8:1775–1782.PubMedGoogle Scholar
  30. 30.
    Watson RJ, Robinson C, Lam EWF (1993). Transcription regulation by murine B-myb is distinct from that by c-myb. Nucleic Acids Res 21:267–272.PubMedCrossRefGoogle Scholar
  31. 31.
    Ness SA, Kowenz-Leutz E, Casini T, Graf T (1993). Myb and NF-M: combinatorial activators of myeloid genes in heterologous cell types. Genes DEV 7:749–759.PubMedCrossRefGoogle Scholar
  32. 32.
    Burk O, Mink S, Ringwald M, Klempnauer KH (1993). Synergistic activation of the chicken mim-1 gene by v-myb and C/EBP transcription factors. EMBO J 12:2027–2038.PubMedGoogle Scholar
  33. 33.
    Kanei-Ishii C, MacMillan EM, Nomura T, Sarai A, Ramsay RG, Aimoto S, Ishii S, Gonda TJ (1992). Transactivation and transformation of MYB are negatively regulated by a leucine-zipper structure. Proc Natl Acad Sci USA 89:3088–3092.PubMedCrossRefGoogle Scholar
  34. 34.
    Nomura T, Sakai N, Sarai A, Sudo T, Kanei-Ishii C, Ramsay RG, Favier D, Gonda TJ, and Ishii S (1993). Negative autoregulation of c-myb activity by homodimer formation through the leucine zipper. J Biol Chem 268:21914–21923.PubMedGoogle Scholar
  35. 35.
    Barletta C, Pelicci PG, Kenyon LC, Smith SD, Dalla-Favera R (1987). Relationship between the c-myb locus and the 6q- chromosomal aberration in leukemias and lymphomas. Science 235:1064–1067.PubMedCrossRefGoogle Scholar
  36. 36.
    Gewirtz AM, Anfossi G, Venturelli D, Valpreda S, Sims R, Calabretta B (1989). G1/S transition in normal human T- lymphocytes requires the nuclear protein encoded by c-myb. Science 245:180–183.PubMedCrossRefGoogle Scholar
  37. 37.
    Jaskulski D, DeRiel JK, Mercer WE, Calabretta B, Baserga R (1989). Inhibition of cellular proliferation by antisense oligodeoxynucleotides to PCNA cyclin. Science 240:1544–1546.CrossRefGoogle Scholar
  38. 38.
    Ku DH, Wen SC, Engelhard A, Nicolaides NC, Lipson KE, Marino TA, Calabretta B (1993). c-myb transactivates cdc2 expression via MYB binding sites in the 5′-flanking region of the human cdc2 gene. J Biol Chem 268:2255–2259.PubMedGoogle Scholar
  39. 39.
    Weber BL, Westin EH, Clarke MF (1990). Differentiation of mouse erythroleukemia cells enhanced by alternatively spliced c-myb mRNA. Science 249:1291–1293.PubMedCrossRefGoogle Scholar
  40. 40.
    Todokoro K, Watson RJ, Higo H, Amanuma H, Kuramochi S, Yanagisawa H, Ikawa Y (1988). Downregulation of c-myb gene expression is a prerequisite for erythropoietin-induced erythroid differentiation. Proc Natl Acad Sci USA 85:8900–••.PubMedCrossRefGoogle Scholar
  41. 41.
    Clarke MF, Kukowska LJ, Westin E, Smith M, Prochownik EV (1988). Constitutive expression of a c-myb cDNA blocks Friend murine erythroleukemia cell differentiation. Mol Cell Biol 8:884–892.PubMedGoogle Scholar
  42. 42.
    Rosson D, O’Brien TG (1995). Constitutive c-myb expression in K562 cells inhibits induced erythroid differentiation but not tetradecanoyl phorbol acetate-induced megakaryocytic differentiation. Mol Cell Biol 15:772–779.PubMedGoogle Scholar
  43. 43.
    Ness SA, Markneil A, Graf T (1989). The v-myb oncogene product binds to and activates the promyelocyte-specific mim-1 gene. Cell 59:1115–1125.PubMedCrossRefGoogle Scholar
  44. 44.
    Nakayama K, Yamamoto R, Ishii S, Nakauchi H (1993). Binding of c-Myb to the core sequence of the CD4 promoter. Int Immunol 5:817–824.PubMedCrossRefGoogle Scholar
  45. 45.
    Reiss K, Ferber A, Travali S. Porcu P, Phillips PD, Baserga R (1991). The protooncogene c-myb increases the expression of insulin-like growth factor 1 and insulin growth factor 1 receptor messenger RNAs by a transcriptional mechanism. Cancer Res 51:5997–6000.PubMedGoogle Scholar
  46. 46.
    Melotti P, Ku DH, Calabretta B (in press). Regulation of the expression of the hematopoietic stem cell antigen CD34: Role of c-myb. J Exp Med.Google Scholar
  47. 47.
    Szczylik C, Skorski T, Ku D-H, Nicolaides NC, Wen S-C, Rudnicke L, Bonati A, Malaguarnera L, Calabretta B (1993). Regulation of proliferation and cytokine expression of bone-marrow fibroblasts: Role of c-myb. J Exp Med 178:997–1005.PubMedCrossRefGoogle Scholar
  48. 48.
    Hijiya N, Zhang J, Ratajczak MZ, DeRiel K, Herlyn M, Gewirtz AM (1994). Biologic and therapeutic significance of Myb expression in human melanoma Proc Natl Acad Sci USA 91:4499–4503.PubMedCrossRefGoogle Scholar
  49. 49.
    Gewirtz AM, Calabretta B (1988). A c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro. Science 242:1303–1306.PubMedCrossRefGoogle Scholar
  50. 50.
    Mucenski ML, McLain K, Kier AB, Swerdlow SH, Schreiner M, Miller TA, Pietryga DW, Scott WJ, Potter SS (1991). A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis. Cell 65:677–689.PubMedCrossRefGoogle Scholar
  51. 51.
    Caracciolo D, Venturelli D, Valiteri M, Peschle C, Gewirtz AM, Calabretta B (1990). Stage-related proliferative activity determines c-myb functional requirements during normal human hematopoiesis. J Clin Invest 85:55–61.PubMedCrossRefGoogle Scholar
  52. 52.
    Calabretta B, Sims RB, Valiteri M, Caracciolo D, Szczylik C, Venturelli D, Ratajczak M, Beran M, Gewirtz AM (1991). Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: An in vitro study relevant to bone marrow purging. Proc Natl Acad Sci USA 88:2351–2355.PubMedCrossRefGoogle Scholar
  53. 53.
    Anfossi G, Gewirtz AM, Calabretta B (1989). An oligomer complementary to c-myb encoded mRNA inhibits proliferation of human myeloid leukemia cell lines. Proc Natl Acad Sci USA 86:3379–3383.PubMedCrossRefGoogle Scholar
  54. 54.
    Ratajczak MZ, Hijiya N, Catan L, DeRiel K, Luger SL, McGlave P, Gewirtz A (1992). Acute and chronic phase chronic myelogenous leukemia colony forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides. Blood 79:1956–1961.PubMedGoogle Scholar
  55. 55.
    Linnenback AJ, Huebner K, Prddy EP, Herlyn M, Parmiter AH, Nowell PC, Koprowski H (1988). Structural alteration in the MYB protooncogene and deletion within the gene encoding a-type protein kinase C in human melanoma cell lines. Proc Natl Acad Sci USA 85:74–78.CrossRefGoogle Scholar
  56. 56.
    Ratajczak M, Kant J, Luger S, Hijiya N, Zhank J, Zon G, Gewirtz A (1992). In vivo treatment of human leukemia in a SCID mouse model with c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 89:11823–11827.PubMedCrossRefGoogle Scholar
  57. 57.
    Luger SM, Ratajczak MZ, Stadtmauer ES, Mangan P, Magee D, Silberstein L, Mdelstein M, Nowell P, Gewirtz AM (1994). Autografting for chronic myelogenous leukemia (CML) with c-myb antisense purged bone marrow: a preliminary report. Blood 84 (Suppl 1):151a.Google Scholar
  58. 58.
    Bedi A, Zehnbauer BA, Collector MI, et al. (1993). BCR-ABL gene rearrangement and expreassion of primitive hematopoietic progenitors in chronic myeloid leukemia. Blood 81:2898–2902.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers, Boston 1996

Authors and Affiliations

  • Alan M. Gewirtz

There are no affiliations available

Personalised recommendations